About RAPT Therapeutics
RAPT Therapeutics is a company based in San Francisco (United States) founded in 2015. It operates as a Professional Services. RAPT Therapeutics has raised $198.74 million across 7 funding rounds from investors including Kleiner Perkins, Orbimed and RTW Investments. The company has 68 employees as of December 31, 2024. RAPT Therapeutics offers products and services including RPT904 and CCR4 Drug Candidates.
- Headquarter San Francisco, United States
- Employees 68 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rapt Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$129.87 M (USD)-11.19as on Dec 31, 2024
-
EBITDA
-$132.56 M (USD)-7.33as on Dec 31, 2024
-
Total Equity Funding
$198.74 M (USD)
in 7 rounds
-
Latest Funding Round
$150 M (USD), Post-IPO
Dec 23, 2024
-
Investors
Kleiner Perkins
& 13 more
-
Employee Count
68
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of RAPT Therapeutics
RAPT Therapeutics is a publicly listed company on the NASDAQ with ticker symbol RAPT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of RAPT Therapeutics
RAPT Therapeutics offers a comprehensive portfolio of products and services, including RPT904 and CCR4 Drug Candidates.
A long-acting anti-IgE antibody for allergic conditions.
Therapies targeting inflammation and cancer immune responses.
People of RAPT Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
16 people
Scientific Team
7 people
Scientist Team
3 people
Finance and Accounting
3 people
Product Management Team
2 people
Sales and Marketing
2 people
Human Resources and Administration
2 people
Software Development Team
2 people
Unlock access to complete
Funding Insights of RAPT Therapeutics
RAPT Therapeutics has successfully raised a total of $198.74M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in RAPT Therapeutics
RAPT Therapeutics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, Orbimed and RTW Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments in US life science startups are focused on.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
US private equity investments are managed by BVF Partners.
|
Locked | Locked | Locked |
Investor details for RAPT Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by RAPT Therapeutics
Investment portfolio details for RAPT Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - RAPT Therapeutics
Detailed financials for RAPT Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rapt Therapeutics Comparisons
Peer comparison for RAPT Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of RAPT Therapeutics
Detailed competitors of RAPT Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rapt Therapeutics
Complete news archive for RAPT Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RAPT Therapeutics
RAPT Therapeutics was founded in 2015.
RAPT Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Brian Wong is the current CEO of RAPT Therapeutics.
RAPT Therapeutics is a funded company, having raised a total of $198.74M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at RAPT Therapeutics is 68.
RAPT Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for inflammatory and immunologic diseases. The company leverages deep expertise in immunology to create molecules that modulate critical immune responses. Its lead candidate, RPT904, targets IgE for allergic conditions like food allergy and chronic spontaneous urticaria. Additionally, CCR4 drug candidates are developed for inflammation and cancer, alongside other early-stage discovery targets. The focus remains on transforming treatment landscapes in these critical healthcare sectors.
RAPT Therapeutics offers RPT904 and CCR4 Drug Candidates.
Yes, RAPT Therapeutics is publicly traded on NASDAQ under the ticker symbol RAPT.
RAPT Therapeutics has 14 investors. Key investors include Kleiner Perkins, Orbimed, RTW Investments, Celgene, and Perceptive Advisors.
The ticker symbol of RAPT Therapeutics is RAPT on NASDAQ.